Multimodal Therapy Impact on Pancreatic Cancer Survival

The goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. The main question it aims to answer is:

Hypothesis: Change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer.

Participants received curative treatment for pancreatic cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoadjuvant Chemotherapy Neoplasms Neoplasms by Site Pancreatectomy Pancreatic Diseases Pancreatic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cheng Kung University Hospital

Tainan, 704, Taiwan

About this study

This study is to analyze the change of treatment strategies and shift of the paradigm over time in a single center. Researchers plan to see the impact of the evolvement to the survival outcomes in pancreatic cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pancreatic adenocarcinoma
Received curative surgery

Exclusion criteria

Other subtypes of pancreatic cancer including acinar cell carcinoma, mucinous carcinoma, undifferentiated carcinoma and intraductal papillary mucinous neoplasm with associated adenocarcinoma
Cases with palliative or R2 resection were also excluded from the analysis.

Treatment and study plan

Primary outcomes

Overall survival and Progression-free survival

Time frame: From enrollment to two years after the end of treatment

Overall survival was calculated from the first treatment day of the disease to the day of mortality. Progression-free survival was calculated from the first treatment day of the disease to the day of proression or recurrece of pancreatic cancer.

Sponsors and collaborators

Lead sponsor

National Cheng Kung University

Other

Registry information

Official study title

Survival Outcome Analysis on the Strategy Shift Integrating a Multimodal Therapy of Neoadjuvant Chemotherapy and Extended Pancreatectomy in Pancreatic Cancer: A Clinical Study From a Retrospective Cohort in a Single Institute

Acronym: MMTIPS

Important dates

Study start: 2011
Primary completion: 2025
Study completion: 2025
First posted: Apr 22, 2025
Registry last updated: Apr 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting